home / stock / fphaf / fphaf quote
Last: | $3.30 |
---|---|
Change Percent: | 0.0% |
Open: | $3.3 |
Close: | $3.30 |
High: | $3.3 |
Low: | $3.3 |
Volume: | 1,654 |
Last Trade Date Time: | 02/11/2022 04:53:46 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$3.3 | $3.3 | $3.3 | $3.3 | $3.3 | 1,654 | 02-11-2022 |
$3.1 | $3.1 | $3.1 | $3.1 | $3.1 | 10,000 | 01-27-2022 |
$3.8412 | $3.8412 | $3.8412 | $3.8412 | $3.8412 | 2,400 | 01-11-2022 |
$3.8208 | $3.8208 | $3.8208 | $3.8208 | $3.8208 | 600 | 01-10-2022 |
$4.7 | $5 | $4.7 | $5 | $4.7 | 3,100 | 09-07-2021 |
$4.8 | $4.8 | $4.8 | $4.8 | $4.8 | 3,000 | 09-06-2021 |
$4.8 | $4.8 | $4.8 | $4.8 | $4.8 | 3,000 | 09-03-2021 |
$4.7 | $4.7 | $4.7 | $4.7 | $4.7 | 10,000 | 09-02-2021 |
$4.7 | $4.7 | $4.7 | $4.7 | $4.7 | 5,000 | 09-01-2021 |
$4.7 | $4.7 | $4.7 | $4.7 | $4.7 | 10,000 | 08-31-2021 |
$5.25 | $5.25 | $5.25 | $5.25 | $5.25 | 4,900 | 08-19-2021 |
$6 | $5.7 | $6 | $6 | $5.7 | 5,100 | 08-09-2021 |
$5.7 | $5.7 | $5.7 | $5.7 | $5.7 | 5,000 | 08-04-2021 |
$5.59 | $5.45 | $5.59 | $5.59 | $5.45 | 4,800 | 07-27-2021 |
$5.5 | $5.5 | $5.5 | $5.5 | $5.5 | 100 | 07-14-2021 |
$5.4999 | $5.4999 | $5.4999 | $5.4999 | $5.4999 | 399 | 06-22-2021 |
$5.5 | $5.5 | $5.5 | $5.5 | $5.5 | 100 | 06-17-2021 |
$5.2106 | $5.2106 | $5.2106 | $5.2106 | $5.2106 | 2,000 | 05-18-2021 |
$5.5 | $5.4 | $5.5 | $5.5 | $5.4 | 2,466 | 01-29-2021 |
$5.3 | $5.3 | $5.3 | $5.3 | $5.3 | 900 | 01-28-2021 |
News, Short Squeeze, Breakout and More Instantly...
Faron Pharmaceuticals Oy Company Name:
FPHAF Stock Symbol:
OTCMKTS Market:
Key highlights Latest readout of the BEXMAB study shows more responding patients and good durability of remission amongst HR HMA-failed MDS patients. 4/5 of the initial Phase 1 HR HMA-failed MDS patients were still alive after eight months of follow-up. While data do not yet all...
(NewsDirect) Faron Pharmaceuticals Limited (AIM:FARN) chief executive Dr Markku Jalkanen joins Proactive's Stephen Gunnion with additional positive data from the Phase 1 study of the ongoing bexmarilimab (BEXMAB) trial that has moved into Phase 2 for higher-risk (HR) myelodysplastic syndr...
TURKU, Finland and BOSTON, March 14, 2024 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvi...